Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab PK in Healthy Chinese Subjects
NCT05268068Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in plaque psoriasis (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events (AE) at 140 days, Maximum Observed Concentration at 140 days and 8 more. Started Jun 2019; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05268068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268068.